$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Can vosoritide be taken for only three days? What is the onset time and usage recommendations?
2026-02-01 22:25:32
Check Details
The pharmacological mechanism and principle of action of mitapivat-Pyrukynd
2026-02-01 22:25:32
Check Details
Safety assessment and study results of Pegcetacoplan-Empaveli
2026-02-01 22:25:32
Check Details
Differences in marketing of Maribavir at home and abroad
2026-02-01 22:25:32
Check Details
Precautions when using Inavolisib
2026-02-01 22:25:32
Check Details
Which company manufactures Datopotamab?
2026-02-01 22:25:32
Check Details
What are the pros and cons of taking Mavakat/Mefanto in patients with cardiac hypertrophy?
2026-02-01 22:25:32
Check Details
Mitapivat-Pyrukynd Market Price Forecast in 2025
2026-02-01 22:25:32
Check Details
Pegcetacoplan-How to deal with side effects of Empaveli
2026-02-01 22:25:32
Check Details
Maribavir/Yitazhi drug interaction cases
2026-02-01 22:25:32
Check Details
Estimated launch time of Inavolisib in the country
2026-02-01 22:25:32
Check Details
Is Datopotamab the same drug as 8201
2026-02-01 22:25:32
Check Details
1
2
...
2281
2282
2283
2284
2285
2286
2287
...
2441
2442
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Hovilpri (Pritelivir) Oral Anti-HSV: Immunocompromised Adults With Acyclovir-Refractory Mucocutaneous Lesions, 63% Healing at 28 Days
2
Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa
3
Emcitate (tiratricol) for MCT8 Deficiency Peripheral Thyrotoxicosis: Bypass MCT8, Lower T3, Monitor Heart Rate and Bone
4
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
5
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
6
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
7
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
8
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
9
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
10
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
11
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
12
Zanvastro (zilganersen-alexander) Intrathecal Injection: First Targeted Therapy for Alexander Disease